71935-16-5 Usage
Uses
Used in Pharmaceutical Research:
CPICA is used as a research compound for its potential biological and pharmaceutical activities. Its unique structure allows it to interact with various proteins and cellular receptors, making it a valuable tool in the development of new drugs and therapies.
Used in Cancer Treatment:
In the field of oncology, CPICA is used as a potential therapeutic agent for cancer treatment. Its ability to target specific cellular receptors and act as a fluorescent probe makes it a promising candidate for the development of targeted cancer therapies.
Used in Anti-Inflammatory Applications:
CPICA is also being investigated for its potential as an anti-inflammatory agent. Its interaction with cellular receptors and proteins could potentially be harnessed to develop new treatments for inflammatory conditions.
Used in Fluorescent Probe Development:
CPICA's fluorescent properties make it a candidate for use as a probe in various research applications. It can be used to detect and study proteins and other biomolecules, contributing to a better understanding of their structures and functions.
Used in Drug Delivery Systems:
Similar to gallotannin, CPICA could potentially be incorporated into drug delivery systems to improve its delivery, bioavailability, and therapeutic outcomes. This could involve the use of organic or metallic nanoparticles as carriers for CPICA, enhancing its efficacy in targeted applications such as cancer treatment or anti-inflammatory therapies.
Check Digit Verification of cas no
The CAS Registry Mumber 71935-16-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,1,9,3 and 5 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 71935-16:
(7*7)+(6*1)+(5*9)+(4*3)+(3*5)+(2*1)+(1*6)=135
135 % 10 = 5
So 71935-16-5 is a valid CAS Registry Number.
71935-16-5Relevant academic research and scientific papers
SEROTONIN 5-HT2B INHIBITORY COMPOUNDS
-
Page/Page column 49-50, (2020/10/18)
The compounds of the invention, as described herein, are novel serotonin 5-HT2B antagonists useful for the treatment of myxomatous mitral valve degeneration (MMVD), congestive heart failure (CHF), and/or asymptomatic heart failure in animals, preferably c
CuI/8-hydroxyquinalidine promoted N-arylation of indole and azoles
Zhang, Yihua,Yang, Xinye,Xing, Hui,Zhang, Ye,Lai, Yisheng,Jiang, Yongwen,Ma, Dawei
experimental part, p. 875 - 880 (2012/05/21)
An efficient catalytic system of CuI/8-hydroxyquinalidine was developed for the coupling of aryl iodides and indole as well as some azoles. The reaction could be carried out at 90°C under the condition of relatively low catalyst loading, affording various
Benzoic acid derivatives and related compounds as antiarrhythmic agents
-
, (2008/06/13)
Benzoic acid derivatives of the formula I where X is oxygen, sulfur, —NH, —NR1, —N—CN, —N—OR1 or —N—NO2; Y is a single bond, —C═C—, or —NH; R1 is alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclo, or (heterocyclo)alkyl; and R2 is aryl or heterocyclo. The compounds of formula I are useful in the treatment of arrhythmia.
Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid
-
, (2011/03/17)
Novel pharmaceutical compositions are disclosed. The compositions comprise an aryl substituted alanine and a substituted phenyl hydrazino propionic acid. The compositions are useful for treating hypertension.
Amino acids and esters thereof useful as antihypertensive agents
-
, (2008/06/13)
A compound of the formula STR1 possesses antihypertensive activity. Also provided are methods for the preparation of the compounds as well as pharmaceutical formulations and methods for their use as antihypertensive agents.
